Figure 7. Maternal OM-85 treatment during pregnancy supports early-life development of the myeloid compartment.

(A–D) Data represent individual 3-week-old naive offspring from mothers treated or not treated with OM-85 during pregnancy. (A) CD103⁺ and (B) CD11b⁺ cDCs as a proportion of total peripheral lung cells. (C) MFI of IAIE expression on peripheral lung CD11b⁺ cDCs. (D) Frequency of cDCs generated following in vitro 7-day GM-CSF–driven bone marrow cultures. (E and F) Data represent individual fetal bone marrow collected at gestation day 18.5 from mothers treated or not treated with OM-85 during pregnancy. Shown are absolute numbers of fetal bone marrow (E) cDCs and (F) MDPs. Data are displayed as box-and-whisker plots showing median, Q₁, and Q₃ and minimum to maximum values of n ≥ 5 independent experiments. Statistical significance was determined using Student’s t test or Mann-Whitney U test and is presented as *P < 0.05, **P < 0.01, ***P < 0.001.